News
PERCF
0.0024
NaN%
--
Percheron Updates Top 20 Option Holders List
TipRanks · 11/06 03:54
Percheron Director Acquires 10 Million Quoted Options
TipRanks · 11/06 01:37
Percheron Releases Top 20 PERAQ Option Holders
TipRanks · 11/06 01:07
Percheron Seeks Quotation of 574.99 Million Options
TipRanks · 11/06 01:07
Percheron Updates Options Issue and Seeks ASX Quotation
TipRanks · 11/03 22:42
Percheron Seeks ASX Quotation for Options Following Prospectus
TipRanks · 11/03 22:41
Percheron Therapeutics Announces Offers For Up To 280 Million New Options
TipRanks · 11/03 22:41
FDA Clears Vanderbilt Trial of Percheron’s HMBD-002 in AML
TipRanks · 11/01 21:40
Percheron Therapeutics Wins ASX Waiver to Quote PERAQ Options After Capital Raising
TipRanks · 10/29 23:39
Percheron bolsters cancer pipeline with new trial, Invion tie-up and fresh leadership
TipRanks · 10/20 00:37
Invion and Percheron Launch Preclinical Cancer Combo Study with Photosoft and VISTA Antibody
TipRanks · 10/19 23:27
Percheron and Invion Launch Preclinical Cancer Combo Study
TipRanks · 10/19 22:10
Percheron Therapeutics seeks ASX quotation for major new share issue
TipRanks · 10/13 22:42
Percheron Grants 75 Million Performance Units to Director Michael Baker
TipRanks · 10/08 02:27
Percheron Therapeutics Issues 75 Million Unquoted Performance Stock Units
TipRanks · 10/08 02:27
Percheron Therapeutics Wins Strong Shareholder Backing at 2026 AGM
TipRanks · 10/07 04:57
Percheron advances HMBD-002 program as transition year reshapes pipeline
TipRanks · 10/06 23:28
Percheron Therapeutics Plans Issue of 75 Million Performance Restricted Stock Units
TipRanks · 10/05 06:20
Percheron Therapeutics Names New CEO to Drive Oncology Strategy and Investor Outreach
TipRanks · 10/04 21:59
Percheron Therapeutics Issues 300 Million New Shares to Institutional and Sophisticated Investors
TipRanks · 09/07 23:01
More
Webull provides a variety of real-time PERCF stock news. You can receive the latest news about Percheron Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About PERCF
Percheron Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on the development and commercialization of novel therapies for oncology and rare diseases. The Company’s lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer. HMBD-002 is a recombinant humanized monoclonal IgG4 antibody to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). VISTA is one of a number of novel immuno-oncology targets under investigation by pharmaceutical companies, with potential applications to a range of solid tumors and hematological malignancies.